Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability

Journal of Clinical Gastroenterology

Volumn 48, Issue 3, 2014, Pages

  Yoon, Eileen L ^a   Yeon, Jong Eun ^a   Lee, Hyun Jung ^a   Suh, Sang Jun ^a   Lee, Sun Jae ^a   Kang, Seong Hee ^a   Kang, Keunhee ^a   Yoo, Yang Jae ^a   Kim, Ji Hoon ^a   Yim, Hyung Joon ^a   Byun, Kwan Soo ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Cytotoxic chemotherapy; Hepatocellular carcinoma; Sorafenib; Survival rate

Indexed keywords

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CISPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; RETROSPECTIVE STUDIES; RISK FACTORS; SIGNAL TRANSDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84894044560     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3182a54ec8     Document Type: Article

References (26)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. Easleortc clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology. 2011;53:1020-1022.
4. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis. 1999;19:329-338.
5. Gish RG, Porta C, Lazar L, et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol. 2007;25:3069-3075.
6. Ishikawa T, Ichida T, Sugitani S, et al. Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage IV-A hepatocellular carcinoma. J Gastroenterol Hepatol. 2001;16:452-459.
7. Lai CL, Wu PC, Chan GC, et al. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer. 1988;62:479-483.
8. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003;37:429-442.
9. Olweny CL, Toya T, Katongole-Mbidde E, et al. Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication. Cancer. 1975;36:1250-1257.
10. Simonetti RG, Liberati A, Angiolini C, et al. Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials. Ann Oncol. 1997;8:117-136.
11. Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/ fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005;97: 1532-1538.
12. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66:11851-11858.
13. Woo HY, Heo J. Sorafenib in liver cancer. Expert Opin Pharmacother. 2012;13:1059-1067.
14. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
15. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.
16. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52-60.
17. National Cancer Institute. Common terminology criteria for adverse events v.3.0. 2006. Available at: Http://ctep.cancer.gov/ protocolDevelopment / electronic-Applications /docs/ctcaev3.pdf. Accessed January 22, 2013.
18. Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: How hopeful should we be? Oncologist. 2006;11: 790-800.
19. Makuuchi M, Kokudo N. Clinical practice guidelines for hepatocellular carcinoma: The first evidence based guidelines from Japan. World J Gastroenterol. 2006;12:828-829.
20. Ryder SD. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut. 2003;52(suppl 3): Iii1-iii8.
21. Iavarone M, Cabibbo G, Piscaglia F, et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy. Hepatology. 2011;54:2055-2063.
22. Lencioni R, Chen XP, Dagher L, et al. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: How can outcomes be improved? Oncologist. 2010;15(suppl 4): 42-52.
23. Lencioni R, Kudo M, Ye SL, et al. First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study. Int J Clin Pract. 2012;66:675-683.
24. Cantarini MC, Trevisani F, Morselli-Labate AM, et al. Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma. Am J Gastroenterol. 2006;101:91-98.
25. Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. J Hepatol. 2012;57:821-829.
26. Tsukui Y, Mochizuki H, Hoshino Y, et al. Factors contributing to the overall survival in patients with hepatocellular carcinoma treated by sorafenib. Hepatogastroenterology. 2012;59:2536-2539.